Innoviva (NASDAQ: INVA) recently received a number of ratings updates from brokerages and research firms:

  • 5/9/2019 – Innoviva was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 5/3/2019 – Innoviva was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 5/3/2019 – Innoviva was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 4/26/2019 – Innoviva was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 4/23/2019 – Innoviva was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 4/17/2019 – Innoviva was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $16.00 price target on the stock. According to Zacks, “Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company’s portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. “
  • 4/16/2019 – Innoviva was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 4/16/2019 – Innoviva was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 4/5/2019 – Innoviva was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Shares of NASDAQ:INVA traded up $0.11 during midday trading on Wednesday, reaching $14.71. The company’s stock had a trading volume of 1,926,244 shares, compared to its average volume of 1,122,735. The company has a market capitalization of $1.44 billion, a PE ratio of 4.17 and a beta of 1.82. The company has a debt-to-equity ratio of 1.93, a current ratio of 66.01 and a quick ratio of 66.02. Innoviva Inc has a 12-month low of $13.07 and a 12-month high of $20.54.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.36 by ($0.05). The firm had revenue of $55.18 million during the quarter. Innoviva had a return on equity of 1,674.72% and a net margin of 151.35%. Equities analysts anticipate that Innoviva Inc will post 1.46 EPS for the current fiscal year.

In other news, Director George Bickerstaff purchased 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 27th. The shares were bought at an average price of $15.90 per share, for a total transaction of $238,500.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Geoffrey Hulme purchased 7,000 shares of the company’s stock in a transaction that occurred on Friday, February 15th. The stock was purchased at an average price of $14.80 per share, for a total transaction of $103,600.00. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 32,000 shares of company stock worth $491,100. 0.18% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Innoviva by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 7,008,172 shares of the biotechnology company’s stock valued at $106,804,000 after acquiring an additional 157,136 shares during the period. Vanguard Group Inc lifted its stake in Innoviva by 2.3% during the 3rd quarter. Vanguard Group Inc now owns 7,008,172 shares of the biotechnology company’s stock valued at $106,804,000 after acquiring an additional 157,136 shares during the period. Renaissance Technologies LLC lifted its stake in Innoviva by 5.4% during the 1st quarter. Renaissance Technologies LLC now owns 6,445,288 shares of the biotechnology company’s stock valued at $90,427,000 after acquiring an additional 332,580 shares during the period. Dimensional Fund Advisors LP lifted its stake in Innoviva by 9.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,553,216 shares of the biotechnology company’s stock valued at $35,822,000 after acquiring an additional 220,799 shares during the period. Finally, LSV Asset Management lifted its stake in Innoviva by 2.4% during the 1st quarter. LSV Asset Management now owns 2,465,871 shares of the biotechnology company’s stock valued at $34,596,000 after acquiring an additional 57,894 shares during the period. Institutional investors own 79.21% of the company’s stock.

Innoviva, Inc engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA.

Read More: Understanding Market Liquidity

Receive News & Ratings for Innoviva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc and related companies with MarketBeat.com's FREE daily email newsletter.